Abstract
The structure of human CTLA-4 reveals that residues Met 99, Tyr 100 and Tyr 104 of the M99 YPPPY104 motif are adjacent to a patch of charged surface residues on the A‘GFCC’ face of the protein. Mutation of these residues, which are conserved in the CTLA-4/CD28 family, significantly reduces binding to CD80 and/or CD86, implicating this patch as a ligand binding site.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Artificial intelligence-powered discovery of small molecules inhibiting CTLA-4 in cancer
BJC Reports Open Access 23 January 2024
-
Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
Scientific Reports Open Access 21 October 2021
-
Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies
Nature Communications Open Access 08 October 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
June, C.H., Bluestone, J.A., Nadler, L.M. & Thompson, C.B. Immunol. Today 15, 321–332 (1994).
Walunas, T.L. et al. Immunity 1, 405–413 (1994).
Krummel, M.F. & Allison, J.P. J. Exp. Med. 182, 459–465 (1995).
Kearney, E.R. et al. J. Immunol. 155, 1032–1036 (1995).
Leach, D.R., Krummel, M.F. & Allison, J.P. Science 271, 1734–1736 (1996).
P., Waterhouse et al. Science 270, 985–988 (1995).
Tivol, E.A. et al. Immunity 3, 541–547 (1995).
Greene, J.L. et al., J. Biol. Chem. 271, 26762–26771 (1996).
Linsley, P.S. et al. J. Biol. Chem. 270, 15417–15424 (1995).
Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L.S., Damle, N.K. & Ledbetter, J.A. J. Exp. Med. 174, 561–570 (1991).
Finck, B.K., Linsley, P.S. & Wofsy, D. Science 265, 1225–1227 (1994).
Wyss, D.F., et al. Science 269, 1273–1278 (1995).
Chothia, C., Novotny, J., Bruccoleri, R. & Karplus, M. J. Mol. Biol. 186, 651–663 (1985).
Peach, R.J. et al. J. Exp. Med. 180, 2049–2058 (1994).
Morton et al., J. Immunol. 156, 1047–1054 (1996).
Truneh, et al., Mol. Immunol. 33, 321–334 (1996).
Kariv, K., Truneh, A. & Sweet, R.W. J. Immunol. 157, 29–38 (1996).
Harris et al., J. Exp. Med. in the press
Clore, G.M. & Gronenborn, A.M. Meth. Enzymol. 239, 349–363 (1994).
Billiter, M., Neri, D., Otting, G., Qian, Y. & Wuthrich, K. J. Biomol. NMR 2, 257–274.
Kuboniwa, H., Grzesiek, S., Delaglio, F., Bax, A. J. Biomol. NMR 4, 871–878 (1994).
Bax, A., Max, D. & Zax, D. J. Amer. Chem. Soc. 114, 6923–6925 (1992).
Vuister, G.W., Wang, A.C. & Bax, A. J. Am. Chem. Soc. 115, 5334–5335 (1993).
AT Brunger, The XPLOR Version 3.1: A system for X-ray Crystallography and NMR (Yale Univ. Press, New Haven, CT) 1993.
Nilges, M., Clore, G.M. & Gronenborn, A.M. FEBS Lett. 229, 317–324 (1988).
Kuszewski, J., Gronenborn, A.M. & Clore, G.M. Prot Sci. 5, 1067–1077 (1996).
M Carson, Ribbons 2.0. J. Appl. Cryst. 24, 958–961 (1991).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Metzler, W., Bajorath, J., Fenderson, W. et al. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nat Struct Mol Biol 4, 527–531 (1997). https://doi.org/10.1038/nsb0797-527
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nsb0797-527
This article is cited by
-
Artificial intelligence-powered discovery of small molecules inhibiting CTLA-4 in cancer
BJC Reports (2024)
-
Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
Scientific Reports (2021)
-
Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies
Nature Communications (2020)
-
Structure Based Screening for Inhibitory Therapeutics of CTLA-4 Unveiled New Insights About Biology of ACTH
International Journal of Peptide Research and Therapeutics (2020)
-
RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4
Scientific Reports (2019)